logo
Candy McCampbell, Tennessean business news pioneer and role model, dies at 78

Candy McCampbell, Tennessean business news pioneer and role model, dies at 78

Yahoo23-04-2025

Candace "Candy" McCampbell, a beloved, respected journalist and pioneer in business news coverage at The Tennessean for three decades, died April 23. She was 78.
"Candy was an outstanding journalist and a wonderful friend," said former U.S. Vice President Al Gore, a Tennessean police reporter in the 1970s and a lifelong Middle Tennessee resident. "She was beloved, trusted and admired by everyone who worked with her."
McCampbell, who joined The Tennessean straight out of college in 1968, became business news editor in 1984 after stints as a features writer, city editor, real estate editor and personal finance writer.
As business editor, McCampbell greatly beefed up The Tennessean's coverage of business news in Middle Tennessee and served as a role model for young reporters, especially women, her former colleagues said.
"Candy was a consummate professional. She had great sources and was respected by those sources," longtime Tennessean colleague Frank Gibson said. "She had a great sense of humor, but when it came to business, she was very serious. There was no playing around."
Longtime former Tennessean copy editor Jennifer Goode Stevens said she looked up to McCampbell.
"[She] was a smart, savvy, outspoken woman who had no qualms about working in a male-dominated news genre. She knew the ins and outs of the Nashville business landscape, who to call and then who to call when that first person was reluctant," Stevens said.
"I was barely 21 when I arrived at The Tennessean," Stevens said. "Candy showed me from the very beginning of my career that success was possible, and that you didn't have to give up being a nice person to have it."
Former longtime Tennessean executive editor Frank Sutherland said McCampbell was passionate about whatever she did in the newsroom.
"She was inclusive, reaching out to people to bring them together," Sutherland said. "Her colleagues valued her counsel, whether as a reporter or editor. And she demanded honesty and truth.
"Her passions made her the superb, respected journalist she was and a valued friend."
When McCampbell retired in 2002 after 33 year at The Tennessean, she said the most memorable story she worked on was the 1982 collapse of a statewide chain of banks owned by brothers Jake and C.H. Butcher, both later convicted of fraud.
"That was the wildest one."
The story she was proudest of: Helping break the news in 1985 that Saturn car manufacturer would open a plant in Tennessee.
Her personality showed clearly in that 2002 interview when she was asked how she saw Nashville's business environment changing in the next 20 years.
'Honey, if I knew that,' she said, 'I wouldn't be sitting here…. I would have been in New York with my crystal ball making lots and lots of money.'
McCampbell grew up the oldest of eight siblings in the Fountain City section of Knoxville. She earned a degree in 1968 from the University of Tennessee, where she served as editor of the school newspaper.
McCampbell started working for The Tennessean the same year she graduated.
After retiring, McCampbell volunteered with the Frist Art Museum and Second Harvest Food Bank, and, a voracious reader, she participated in several book clubs. McCampbell often was spotted walking around her Belle Meade neighborhood chatting with neighbors and petting their dogs.
McCampbell also wrote some freelance journalism articles and spent time visiting with a plethora of nieces, nephews, great-nieces and great-nephews.
She is survived by those who called her 'aunt' and by all seven of her siblings, her brothers, Joe McCampbell (Vicki) of Bartlett, Tenn., Harrison McCampbell (Linda) of Brentwood, and Jim McCampbell (Jennifer) of Knoxville; and her sisters, Cindy McCampbell Cross of Choteau, Montana, Martha Lou McCampbell of Maryville, Tenn., Rosemary McCampbell of Seymour, Tenn., and Lee Smith of Greensboro, N.C.
Funeral arrangements have not been set as of the posting of this story.
The family suggests donations to the Frist Art Museum and Second Harvest Food Bank to honor McCampbell's memory.
Reach Brad Schmitt at brad@tennessean.com.
This article originally appeared on Nashville Tennessean: Candy McCampbell, former Tennessean business news journalist, dies

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Powering Retail's Future: PXP Brings Castles Technology's Android Terminals to Global Merchants
Powering Retail's Future: PXP Brings Castles Technology's Android Terminals to Global Merchants

Business Wire

time05-06-2025

  • Business Wire

Powering Retail's Future: PXP Brings Castles Technology's Android Terminals to Global Merchants

LONDON--(BUSINESS WIRE)--PXP, a next-gen payment platform, today announces a strategic collaboration with Castles Technology, bringing cutting-edge Android-based terminal technology to merchants of all sizes across diverse point-of-sale environments. This powerful partnership combines PXP's innovative payment expertise with Castles Technology's advanced hardware engineering to deliver a seamless, secure payment experience that elevates customer engagement in every business context. "We're excited to partner with Castles Technology to expand our hardware ecosystem and bring these innovative Android payment solutions to our customers," said Kamran Hedjri, CEO at PXP. 'From day one, Castles Technology has distinguished themselves as an extraordinarily responsive and collaborative partner. Their team's unwavering commitment to excellence, technical expertise, and customer-first approach perfectly mirrors our own values, making this collaboration particularly powerful. "This partnership represents our commitment to providing merchants with the most advanced, reliable, and user-friendly payment technologies in today's rapidly evolving marketplace. As we continue to build on our tech-first approach following the launch of PXP Unity and our recent PXP POS standalone solution, this partnership aligns perfectly with our vision of creating a truly unified global commerce ecosystem." The collaboration brings PXP's platform together with Castles Technology's latest Saturn terminal range, creating a solution that elevates payment experiences through: Cutting-Edge Technology Access: Merchants gain immediate access to state-of-the-art Android payment terminals featuring the latest security protocols, intuitive interfaces, and enhanced customer engagement features. Versatile Terminal Solutions: The new terminal lineup includes sleek, space-efficient designs engineered for today's point-of-sale environments, offering enhanced connectivity, lightning-fast transaction processing, and support across multiple form factors including mobile, countertop, and unattended terminals. Streamlined Implementation: This partnership delivers a significantly expedited fulfillment process, with faster equipment delivery and setup, minimising business disruption and accelerating time-to-value for merchants of all sizes. Unified Commerce Experience: PXP will embed real-time data insights and granular control over merchants' payment ecosystem across all channels into the solution, breaking down borders and unifying commerce operations worldwide. James Lotz, SVP Northern & Western Europe added, "Our collaboration with PXP creates a powerful opportunity to extend our reach and equip merchants with Android payment terminals specifically designed for today's demanding instore landscape. We're proud to support PXP's customers with our innovative hardware solutions that combine security, reliability, and enhanced user experience." The announcement comes at a pivotal moment for PXP, following the company's recent brand transformation and the successful launch of its groundbreaking PXP Unity platform earlier this year. The new Android terminal offerings will be available to PXP customers starting May 2025, complementing the recently launched PXP POS standalone solution as part of the company's strategic expansion of its point-of-sale ecosystem. This integration aligns with PXP's vision to deliver comprehensive payment solutions that meet evolving merchant needs across all channels. For more information, please visit or About PXP PXP is a tech platform that makes commerce simpler, better, and more connected. With just one connection to PXP, merchants can unlock a world of commerce across online, mobile, and point-of-sale channels. Powered by a suite of financial services, multiple acquiring connections—including an in-house acquiring license—and diverse alternative payment methods, PXP processes over €30 billion annually through our unified gateway. Connect once to our global commerce ecosystem to supercharge your growth by unifying payments, streamlining operations, and getting access endless opportunities. Learn more about the PXP family of companies at: About Castles Technology Castles Technology is a global leader in payment acceptance solutions, providing cutting-edge terminals, innovative solutions, and differentiated services to strengthen the payment ecosystem. Present in 150 countries and with a team of over 1,000 employees, Castles Technology partners with thousands of clients—including banks, merchants, FinTechs, acquirers, ISVs, and PSPs—to deploy millions of point-of-sale terminals worldwide, catering to businesses of all sizes. As a pioneer in Android payment acceptance, Castles Technology delivers secure, reliable, and scalable solutions, having recently launched its third generation of Android terminals. With over 30 years of expertise, the company continues to drive the evolution of commerce by developing state-of-the-art payment solutions and first-class services, ensuring unmatched quality and performance for its partners. Committed to a more sustainable future, Castles Technology integrates eco-design into its products, optimizes operations, and develops responsible services to minimize its environmental footprint and create a positive impact on the planet.

Halo Biosciences Announces Thorax Publication of Phase 2a SATURN Study Results in PH-ILD
Halo Biosciences Announces Thorax Publication of Phase 2a SATURN Study Results in PH-ILD

Business Wire

time04-06-2025

  • Business Wire

Halo Biosciences Announces Thorax Publication of Phase 2a SATURN Study Results in PH-ILD

PALO ALTO, Calif.--(BUSINESS WIRE)--Halo Biosciences ('Halo'), a clinical-stage biotechnology company developing extracellular matrix-targeted therapies, today announced publication of results from the Phase 2a SATURN study in Thorax. The study, conducted at Stanford University, evaluated 4-methylumbelliferone (4-MU) in patients with pulmonary hypertension, a highly progressive disease with significant unmet needs. The SATURN study, a Phase 2a randomized, double-blind, placebo-controlled trial, enrolled 16 patients with pulmonary hypertension. 4-MU was safe and well-tolerated throughout the 24-week treatment period. The primary hemodynamic measurement of change in pulmonary vascular resistance was not statistically significant. Among patients with PH-ILD, prespecified exploratory efficacy signals showed a mean improvement of 66 meters in six-minute walk distance and enhanced quality-of-life scores. These findings support further clinical evaluation of 4-MU as a potential disease-modifying therapy for inflammatory and fibrotic lung diseases. 'These clinical data reinforce the scientific rationale for targeting hyaluronan in fibrotic and inflammatory lung disease and highlight 4-MU's potential as a first-in-class, disease-modifying ECM-modulator for patients with serious conditions like PH-ILD,' said Paul Bollyky, M.D., professor of medicine at Stanford University and scientific co-founder of Halo Biosciences. 'This represents a meaningful step forward for individuals living with PH-ILD, a condition with limited treatment options and a high burden of disease.' HB-1614, Halo's lead investigational therapy, is a proprietary, oral formulation of 4-MU optimized for improved bioavailability and long-term use in patients with chronic lung conditions such as PH-ILD. By inhibiting hyaluronan synthesis, HB-1614 targets a key driver of extracellular matrix (ECM) remodeling involved in inflammation and fibrosis—processes central to disease progression in several debilitating diseases, including PH-ILD. 'We are proud to see the SATURN study featured in Thorax, validating our translational approach and marking a key milestone in our development of HB-1614,' said Anissa Kalinowski, chief executive officer of Halo Biosciences. 'We are thankful to Stanford University and sponsor investigators Roham Zamanian, M.D., and Vinicio de Jesus Perez, M.D., for their leadership of the SATURN trial, unlocking the potential of this new mechanism of action.' Halo Biosciences is progressing clinical development of HB-1614 and exploring partnership opportunities to accelerate its work in PH-ILD and other fibrotic conditions. The company holds exclusive intellectual property for its formulation and is positioned to optimize drug delivery, bioavailability and regulatory strategy. The full manuscript is now available online. To access the paper, visit: ABOUT HB-1614 HB-1614 is Halo Biosciences' lead investigational therapy, a proprietary formulation of 4-methylumbelliferone (4-MU) designed to inhibit hyaluronan synthesis, a key driver of inflammation and fibrosis in the ECM. By targeting this dysregulated pathway, HB-1614 offers a novel, disease-modifying approach for conditions like pulmonary hypertension associated with interstitial lung disease (PH-ILD). ABOUT PULMONARY HYPERTENSION Pulmonary hypertension (PH) is a progressive condition caused by elevated blood pressure in the arteries of the lungs, leading to reduced oxygen exchange, right heart strain, and eventual heart failure. i Symptoms include breathlessness, fatigue, and dizziness ii. PH diagnosis is often delayed and accompanied by comorbidities, with most patients diagnosed between the ages of 60 and 70 iii. When PH is associated with interstitial lung disease (PH-ILD), the course of disease is often more accelerated, with these patients facing a median survival of just 2 to 5 years. iv Currently, there is only one FDA-approved therapy for PH-ILD, iv leaving a significant unmet need for therapies that target the underlying mechanisms of disease progression. New approaches are urgently needed to improve outcomes and quality of life for this vulnerable patient population. ABOUT HALO BIOSCIENCES Halo Biosciences is a clinical-stage biopharmaceutical company targeting the extracellular matrix (ECM) to transform the treatment of diseases characterized by inflammation and fibrosis. It is headquartered in Palo Alto, CA. For more information, visit i Pulmonary Fibrosis Foundation. Pulmonary Hypertension Related to Interstitial Lung Disease (for Patients). Retrieved from ii Pulmonary Hypertension Association. Diagnosing Pulmonary Hypertensio n. Accessed on June 3, 2025 from iii Mount Sinai Health System. (n.d.). Idiopathic pulmonary fibrosis. Mount Sinai Health Library. Retrieved June 3, 2025, from iv Nathan, S. D., Stinchon, M. R., Atcheson, S., Simone, L., & Nelson, M. (2025). Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment. Journal of Managed Care & Specialty Pharmacy, 31(1-a Suppl), S2–S29.

UT Haslam in Top Five Among U.S. Public Schools in Major International Ranking for Ninth Year
UT Haslam in Top Five Among U.S. Public Schools in Major International Ranking for Ninth Year

Yahoo

time02-06-2025

  • Yahoo

UT Haslam in Top Five Among U.S. Public Schools in Major International Ranking for Ninth Year

Haslam holds the No. 5 place among U.S. public institutions in The Financial Times' 2025 Custom Executive Education Ranking. KNOXVILLE, Tenn., June 2, 2025 /PRNewswire/ -- In The Financial Times' 2025 Custom Executive Education Ranking released today, the University of Tennessee, Knoxville, Haslam College of Business placed No. 5 among U.S. public institutions. Marking nine years of excellence, Haslam's custom executive education programs continue to rank in the top five among U.S. public institutions. Haslam ranked No. 7 among all public and private U.S. schools, and No. 53 among all business schools worldwide. In the rankings' growth subcategory, Haslam rose above all other U.S. public universities, ranking No. 1 for the second consecutive year. Focused on Students, Delivering Value Amy Cathey, Haslam's associate dean for graduate and executive education and interim vice provost and dean of the UT Graduate School, described the rankings as a testament to the college's ability to deliver timely and impactful executive education through impactful and rigorous academic experiences. "Our faculty and staff make every effort to provide our students with the most current and relevant experiential learning possible," she said. "The expertise they acquire in these programs equip them to deliver significant value to their organizations. We are mindful that the business professionals who choose to augment their skills with Haslam have busy career demands, and we strive to accommodate their schedules by meeting them where they are with many programming options." Haslam offers a full portfolio of customized executive education programs, open enrollment short courses, multiple MBA programs and several specialty masters' programs. About the Financial Times' Custom Executive Education Ranking The Financial Times' Custom Executive Education Ranking is widely acknowledged as an authoritative source, respected for the thoroughness and balance of its methodology. The rankings are derived from a client survey and a school survey and consider many factors. These elements include the quality of instruction, flexibility of program design, relevance to the workplace of new skills learned, follow up with students and several other data points. A total of 101 institutions from around the globe were included. View original content to download multimedia: SOURCE University of Tennessee on behalf of its Haslam College of Business Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store